Press releases
NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product
This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)
Update on coronavirus (2019-nCoV) situation
In response to the rapidly developing Covid-19 epidemic, governments around the world are strengthening preventive and precautionary measures to limit the spread of the virus and protect populations.
Novasep implements new Biopharma Solutions Business Unit, led by Cédric Volanti
The new Biopharma Solutions Business Unit is created to support Novasep’s growth strategy, Rise-2, and includes all Novasep Belgium activities. Cédric Volanti has joined Novasep to lead this new BU and will be a member of Novasep’s Executive Committee.
Fire brought under control at our site in Chasse-sur-Rhône: no injury or damage
A fire broke out this morning around 4:20 am outside of a small production workshop at our site in Chasse-sur-Rhône.
Novasep launches oXYgene™, a fully integrated offer for boosting viral vector production
Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique
2-year turnkey plant offer to accelerate commercial production of viral vectors.
Senefill, Novasep's commercial facility for aseptic filling and finishing operations, is now ready to operate.
Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging.
NOVASEP and THERAVECTYS enter into a new license agreement on DNA Flap Technology for GMP Manufacturing of lentiviral vectors
This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines
Novasep announces the success of its consent solicitation extending the maturity of its notes
• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated
Enzene Biosciences chooses Novasep BioSC® Pilot chromatography for its automated end to end continuous manufacture of mAb.
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.
Novasep announces the launch of a consent solicitation for the maturity extension of notes with requisite voting majority of the noteholders already secured
Novasep Holding S.A.S (“Novasep”), a leading supplier of services and technologies for the life sciences industry, announces the launch of a consent solicitation (the “Consent Solicitation”) in order to, inter alia: